

Clinical Analysis of Multidrug Resistance-Related Protein Expression in Gastric Cancer Cells

Xiaomeng Chen, Xinyu Zheng, Xiaoxiao Zhou, Wenzhen Wang, Qian Liu, Xingzhou Xia*

The fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China, Email: zhouxia@163.com

Fund project: Project source: Henan Provincial Medical Science and Technology Research Plan Key project jointly built by the Ministry, No.: SBGJ202002093; Henan Provincial Medical Science and Technology Research Project, No.: LHGJ20190428.

Abstract: Objective: This study aims to clinically analyze the expression of multidrug resistance-related proteins in gastric cancer cells. Methods: In this study, archival paraffin blocks from 50 surgical specimens of gastric cancer collected in our hospital between 2021 and 2022 were included. Each specimen included tumor lesion tissue and normal gastric mucosa tissue located more than 5 cm away from the cancer. Immunohistochemistry was performed to detect P-glycoprotein (P-gp), glutathione S-transferase pi (GST- π), and B-cell lymphoma-extra-large (Bcl-xL) expression, and the relevant data were collected and analyzed. Results: The positive expression rates and high expression levels of P-gp, GST- π , and Bcl-xL in gastric cancer tissues were significantly higher than in normal gastric mucosa tissues ($p < 0.05$). The expression of multidrug resistance proteins (P-gp, GST- π , Bcl-xL) in gastric cancer was not associated with patient clinical characteristics (tumor clinical stage, depth of invasion, and lymph node metastasis) ($p > 0.05$); Bcl-xL expression level was positively correlated with tumor differentiation degree ($p < 0.05$). Conclusion: The results of this study reveal the expression patterns of multidrug resistance-related proteins in gastric cancer tissues and shed light on the relationship between the expression of these proteins and multidrug resistance in gastric cancer.

Keywords: Gastric cancer cells; multidrug resistance-related proteins; clinical analysis

Gastric cancer, as a common malignant tumor worldwide, has maintained high incidence and mortality rates. According to data from the World Health Organization, gastric cancer is the third leading cause of cancer-related deaths globally [1]. High-incidence areas for gastric cancer primarily include regions such as Asia, Latin America, Eastern Europe, and Africa. The occurrence of gastric cancer is closely linked to factors such as diet, environment, and genetics, and its early symptoms are often subtle, leading to many patients being diagnosed at an advanced stage. Surgical intervention remains the primary treatment method for gastric cancer [1, 2]. Multidrug resistance poses a significant challenge in the treatment of gastric cancer, severely impacting patient prognosis and treatment outcomes [3]. Multidrug resistance refers to the simultaneous resistance of cancer cells to multiple chemotherapeutic drugs [4], leading to treatment failure and recurrence. Currently, the study of multidrug resistance mechanisms has become a hot topic in the field of gastric cancer treatment; however, many aspects of the specific mechanisms and the expression of related proteins remain unknown. Analyzing the expression of

multidrug resistance-related proteins within gastric cancer cells, exploring their roles and significance in the development of gastric cancer, and providing new targeted treatment strategies for gastric cancer are discussed in this study. The details are as follows:

1. Materials and Methods

1.1 General Information

In this study, archival paraffin blocks from 50 surgical specimens of gastric cancer, collected between 2021 and 2022 at our institution, were included. Each specimen consisted of both tumor lesion tissue and normal gastric mucosa tissue located more than 5 cm away from the cancer. These specimens were derived from 30 male and 20 female patients, with ages ranging from 26 to 88 years. Notably, the selected cases had not undergone any prior antitumor treatment. Patient demographics, including age, gender, and clinical pathological data related to gastric cancer, were thoroughly documented. This data encompassed the clinical stage of the tumor, depth of invasion, degree of differentiation, and lymph node involvement. According to the international TNM classification for cancer staging, our study sample included 7 cases of Stage I gastric cancer, 6 cases of Stage II gastric cancer, 22 cases of Stage III gastric cancer, and 15 cases of Stage IV gastric cancer. Based on the World Health Organization's histological classification, the study sample included 23 cases of poorly differentiated adenocarcinoma, 13 cases of moderately differentiated adenocarcinoma, 7 cases of well-differentiated adenocarcinoma, and 7 cases of signet ring cell carcinoma. Well-differentiated and moderately differentiated adenocarcinomas were categorized as the differentiated group, while poorly differentiated adenocarcinoma and signet ring cell carcinoma were classified as the undifferentiated group. Additionally, 35 patients had lymph node metastasis, while 15 patients did not.

1.2 Methods

1.2.1. Sectioning

Archival paraffin blocks were cut into 4-5 μ m thick sections and placed on glass slides. The sections were baked at 56° C for 1 hour to ensure their complete adhesion to the glass slides.

1.2.2. Deparaffinization to Water

The sections were immersed in xylene three times for 15 minutes each. Subsequently, they were sequentially placed in 100%, 95%, 75%, and 50% ethanol solutions for 2 minutes each to dehydrate. The sections were rinsed with phosphate-buffered saline (PBS) and soaked in PBS for 5 minutes.

1.2.3. Antigen Retrieval and Blocking

The sections were placed in EDTA antigen retrieval solution and microwaved for 5 minutes, followed by cooling to room temperature. 5% BSA was added to the sections, and they were incubated at 37° C for 30 minutes.

1.2.4. Antibody Incubation

Specific antibodies against P-glycoprotein (P-gp), glutathione S-transferase pi (GST- π), and B-cell lymphoma-extra-large (Bcl-xL) were added separately to the sections and incubated at 37° C for 2 hours. The sections were then washed with

PBS to remove unbound antibodies. Corresponding secondary antibodies were added to the sections and incubated at 37° C for 30 minutes. The sections were rinsed in PBS three times, each time for 5 minutes.

1.2.5. Staining and Observation

The prepared 3,3'-diaminobenzidine (DAB) staining solution was dropped onto the sections, and the reaction was stopped after an appropriate staining time. Hematoxylin counterstaining was performed for 40 seconds, followed by rinsing in water and immersion in bluing reagent for 1 minute. After gradient alcohol dehydration and xylene clarification, the sections were coverslipped with neutral resin. They were then observed and photographed under a microscope.

1.2.6. Result Analysis

The staining results were evaluated by considering the combined positive staining intensity and the proportion of positively stained cells. Positive staining intensity was graded as 0 (no cell staining), 1 (pale yellow granules), 2 (tan granules), and 3 (brown granules). Positive cell proportion was graded as 0 ($\leq 10\%$), 1 (11% – 50%), 2 (51% – 75%), and 3 (>75%). The positive labeling score was calculated as the product of the positive staining intensity grade and the positive cell proportion grade, resulting in four levels: (-), (+), (++) , and (+++), where (++) and (+++) represent high expression.

1.3 Statistical Methods

Data were processed using SPSS 26.0 statistical software. Count data were expressed as mean \pm standard deviation ($\pm s$) and analyzed using t-tests. Percentage data were analyzed with chi-squared tests to determine whether there were significant differences between two groups ($P < 0.05$).

2. Results

2.1 Expression of P-gp, GST- π , and Bcl-xL

The positive expression rates and high expression levels of P-glycoprotein (P-gp), glutathione S-transferase pi (GST- π), and B-cell lymphoma-extra-large (Bcl-xL) in gastric cancer tissues were significantly higher than those in normal gastric mucosa tissues ($p < 0.05$). Specific data are presented in Table 1 and Table 2.

Group	Example number	P-gp				GST- π				Bcl-xL			
		-	+	++	+++	-	+	++	+++	-	+	++	+++
Gastric cancer tissue	50	30	10	8	2	20	15	7	8	7	15	15	13
Normal gastric mucosal tissue	50	48	2	0	0	45	5	0	0	40	10	0	0

Table 1 Specific expression profiles of P-gp, GST- π , and Bcl-xL

Group	Example number	P-gp		GST- π		Bcl-xL	
		Positive rate	High expression rate	Positive rate	High expression rate	Positive rate	High expression rate
Gastric cancer tissue	50	40	20	60	30	86	56
Normal gastric mucosal tissue	50	4	0	10	0	20	0
χ^2		36.029	11.111	27.473	17.647	43.717	38.889
p		0.000	0.000	0.000	0.000	0.000	0.000

Table 2 Specific expression profiles of P-gp, GST- π , and Bcl-xL, (%)

2.2 Occurrence of Nursing Risks

The expression of multidrug resistance proteins, P-glycoprotein (P-gp), glutathione S-transferase pi (GST- π), and B-cell lymphoma-extra-large (Bcl-xL), in gastric cancer was not associated with patient clinical characteristics, including tumor clinical stage, depth of invasion, degree of differentiation, and lymph node metastasis ($p > 0.05$). Detailed data are provided in Table 3.

Group	Example number	P-gp				P
		-	+	++	+++	
Sex						0.368
Male	30	19	6	5	0	
Female	20	11	4	3	2	
Age						0.419
>62	26	15	6	5	0	
≤62	24	15	4	3	2	
Degree of differentiation						0.067
Differentiated	20	12	2	6	0	
Differential type	30	18	8	2	2	
Infiltration depth						0.251
The plasma membrane was not involved	18	9	6	3	0	
Involve the plasma membrane	32	21	4	5	2	
lymphatic metastasis						0.860

None	15	8	3	3	1	
Have	35	22	7	5	1	
Clinical stages						0.450
I	7	4	2	1	0	
II	6	4	1	1	0	
III	22	16	2	2	2	
IV	15	6	5	4	0	
Group	Example number	Bcl-xL				<i>P</i>
		-	+	++	+++	
Sex						0.858
Male	30	4	8	9	9	
Female	20	3	7	6	4	
Age						0.060
>62	26	1	7	8	10	
≤62	24	6	8	7	3	
Degree of differentiation						0.025
Differentiated	20	1	7	3	9	
Differential type	30	6	8	12	4	
Infiltration depth						0.057
The plasma membrane was not involved	18	5	4	7	2	
Involve the plasma membrane	32	2	11	8	11	
lymphatic metastasis						0.618
None	15	3	4	3	5	
Have	35	4	11	12	8	
Clinical stages						0.665
I	7	2	2	2	1	
II	6	0	1	3	2	
III	22	4	5	7	6	
IV	15	1	7	3	4	
Group	Example number	GST-π				<i>P</i>
		-	+	++	+++	
Sex						0.858
Male	30	14	6	5	5	

Female	20	6	9	2	3	
Age						0.249
>62	26	11	6	5	4	
≤62	24	9	9	2	4	
Degree of differentiation						0.888
Differentiated	20	8	5	3	4	
Differential type	30	12	10	4	4	
Infiltration depth						0.472
The plasma membrane was not involved	18	9	3	3	3	
Involve the plasma membrane	32	11	12	4	5	
lymphatic metastasis						0.440
None	15	8	3	1	3	
Have	35	12	12	6	5	
Clinical stages						0.591
I	7	3	2	1	1	
II	6	3	1	1	1	
III	22	12	6	2	2	
IV	15	2	6	3	4	

Table 3: Relationship between Biological Behavior of P-gp, GST- π , and Bcl-xL in Gastric Cancer Tissues

3. Discussion

Multidrug resistance in gastric cancer cells refers to the phenomenon in which these cells develop resistance to multiple chemotherapy drugs simultaneously.[5] Understanding the mechanisms of multidrug resistance is crucial for improving the effectiveness of gastric cancer treatment and developing personalized treatment strategies.[6-7] The mechanisms of multidrug resistance primarily involve the action of drug efflux pumps and the influence of cellular signaling pathways. Drug efflux pumps play a significant role in gastric cancer cells by expelling chemotherapy drugs from the cells, reducing drug accumulation inside the cells, and decreasing drug toxicity. Drug efflux pumps can be categorized into active and passive transport. Active transport involves the expulsion of drugs from the cell through specific transport proteins, with members of the ABC transporter family being the most common. Overexpression of these transporters can increase resistance to various chemotherapy drugs.[8-9] Passive transport involves regulating cell membrane permeability and drug-binding protein expression, impacting the distribution of drugs within and outside the cells. Cellular signaling pathways play a crucial regulatory role in multidrug resistance in gastric cancer cells, with the abnormal

activation of multiple signaling pathways leading to increased resistance to chemotherapy drugs. One significant signaling pathway is the PI3K/Akt/mTOR pathway,[10] which, when activated, promotes cell proliferation, survival, and transcription factor activity, ultimately reducing the cytotoxic response to chemotherapy drugs.[11-12] Another vital signaling pathway is the NF- κ B pathway, a transcription factor closely associated with multidrug resistance in gastric cancer cells.[13] Activation of NF- κ B can regulate the expression of anti-apoptotic proteins, making cancer cells resistant to the apoptotic effects of chemotherapy drugs.[14-15]

Multidrug resistance-related proteins include members of the ABC transporter family.[16-17] These transporters play a central role in multidrug resistance mechanisms, effectively transporting chemotherapy drugs inside and outside the cell, thus reducing drug accumulation within the cells.[18] Common ABC transporters include P-glycoprotein (P-gp, ABCB1), and breast cancer resistance protein (BCRP, ABCG2), both of which are closely associated with multidrug resistance in gastric cancer cells.[19-20] P-gp is one of the most widely studied transport proteins related to multidrug resistance in gastric cancer.[21] It transports chemotherapy drugs inside and outside the cell, reducing drug accumulation inside the cells. Overexpression of BCRP in gastric cancer cells increases resistance to several chemotherapy drugs. Additionally, drug-metabolizing enzymes play a vital role in multidrug resistance within gastric cancer cells.[22-23] These enzymes metabolize chemotherapy drugs, reducing their cellular toxicity and treatment efficacy. Drug-metabolizing enzymes mainly include members of the cytochrome P450 (CYP450) family and uridine diphosphate glucuronosyltransferases (UGT).[24-26] In gastric cancer cells, abnormal expression and activation of these multidrug resistance-related proteins mutually affect each other and collectively contribute to the development and maintenance of multidrug resistance. Understanding the mechanisms of action of these proteins can help identify new therapeutic targets and enhance the efficacy of chemotherapy in gastric cancer.

In this study, we utilized immunohistochemical staining to assess the expression of P-gp, GST- π , and Bcl-xL in gastric cancer tissues and normal gastric mucosa tissues. In gastric cancer tissues, the levels of P-gp, GST- π , and Bcl-xL expression were significantly higher than those in normal gastric mucosa tissues ($p < 0.05$). This suggests that P-gp, GST- π , and Bcl-xL are overexpressed in gastric cancer. In gastric cancer tissues, the expression levels of P-gp and GST- π were significantly higher than those in normal gastric mucosa tissues, typically displaying low to moderate positive expression as "+" or "++." Conversely, Bcl-xL exhibited relatively high expression levels, often presenting as high-intensity positive expression as "+++" or "++++." Multidrug resistance is a significant issue in gastric cancer treatment, greatly limiting the efficacy of chemotherapy drugs. Our research results indicate that the high expression of P-gp, GST- π , and Bcl-xL in gastric cancer tissues is closely related to multidrug resistance. P-gp contributes to multidrug resistance by actively transporting various chemotherapy drugs inside and outside the cell, reducing drug accumulation inside the cell. On the other hand, GST- π participates in drug metabolism and detoxification processes, reducing the cytotoxicity and therapeutic

effects of chemotherapy drugs. The overexpression of Bcl-xL in gastric cancer tissues may be associated with aberrations in the apoptosis process, further increasing resistance to chemotherapy drugs.[27]

The expression of multidrug resistance-related proteins is closely related to the prognosis and treatment outcomes of gastric cancer. The results of this study provide a pattern of expression for multidrug resistance-related proteins in gastric cancer, offering critical insights for personalized treatment of gastric cancer. Given the close association between the overexpression of P-gp, GST- π , and Bcl-xL and multidrug resistance, inhibiting the function of these proteins may help improve the efficacy of chemotherapy drugs in gastric cancer treatment.[28-30] There are already inhibitors or antagonists developed for P-gp, GST- π , and Bcl-xL that can serve as candidate drugs for gastric cancer treatment, further enhancing treatment efficacy.[31-33] Additionally, in the analysis of their correlation with clinical characteristics, it was found that the expression level of Bcl-xL, one of the multidrug resistance-related proteins, was positively correlated with the degree of tumor differentiation. This suggests that the overexpression of multidrug resistance-related proteins in gastric cancer tissues may be related to the invasiveness and malignancy of tumors.

However, there are some limitations to this study. First, the sample size was relatively small, which may limit the reliability and generalizability of the results. Expanding the sample size and conducting multicenter and multiethnic clinical studies can better validate our results and enhance their reliability and applicability. Second, this study only examined the expression of multidrug resistance-related proteins at the tissue level and did not explore their genetic aspects. Subsequent research can comprehensively investigate their functions and regulatory mechanisms by analyzing the gene expression or mutation status of these proteins. Additionally, all the research was based on a single assessment, and there was no tracking observation of the long-term treatment response and prognosis of the patients. Subsequent research can validate the relationship between the expression of these proteins and treatment outcomes through long-term follow-up.

In conclusion, through a clinical analysis of the expression of multidrug resistance-related proteins in gastric cancer cells, this study reveals the expression pattern of these proteins in gastric cancer tissues and elucidates their relationship with multidrug resistance in gastric cancer. This provides important insights for personalized gastric cancer treatment and the development of novel drugs. Future research can further expand the sample size and scope of the study, explore the regulatory mechanisms of multidrug resistance-related proteins, integrate them with other clinical information, and achieve more precise gastric cancer treatment. This will offer better treatment options and prognosis assessment for gastric cancer patients and provide more effective strategies and methods for gastric cancer treatment.

Reference:

- [1] Smyth, E.C., et al., Gastric cancer. *Lancet*, 2020. 396(10251): p. 635-648.
- [2] Tan, Z., Recent Advances in the Surgical Treatment of Advanced Gastric Cancer: A

Review. *Med Sci Monit*, 2019. 25: p. 3537-3541.

[3] Wang, Q., et al., APAF1-Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly. *Adv Sci (Weinh)*, 2022. 9(28): p. e2201889.

[4] Fernandes, E.S.E., et al., C-Phycocyanin: Cellular targets, mechanisms of action and multi drug resistance in cancer. *Pharmacol Rep*, 2018. 70(1): p. 75-80.

[5] Wu, Y., et al., Impact of MiRNAs and LncRNAs on Multidrug Resistance of Gastric Cancer. *Comb Chem High Throughput Screen*, 2022. 25(13): p. 2127-2140.

[6] Czipiel, P.P., V. Delplace, and M.S. Shoichet, Cationic block amphiphiles show anti-mitochondrial activity in multi-drug resistant breast cancer cells. *J Control Release*, 2019. 305: p. 210-219.

[7] Wang, M., et al., Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies. *Eur J Med Chem*, 2021. 220: p. 113487.

[8] Bonitto, E.P., B.T. McKeown, and K.B. Goralski, Jadomycins: A potential chemotherapy for multi-drug resistant metastatic breast cancer. *Pharmacol Res Perspect*, 2021. 9(6): p. e00886.

[9] Wang, Y., et al., The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. *Expert Opin Drug Metab Toxicol*, 2021. 17(3): p. 291-306.

[10] He, J., et al., LncRNA as a multifunctional regulator in cancer multi-drug resistance. *Mol Biol Rep*, 2021. 48(8): p. 1-15.

[11] Xu, F., et al., Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. *Cell Biosci*, 2020. 10(1): p. 54.

[12] Tewari, D., et al., Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. *Semin Cancer Biol*, 2022. 80: p. 1-17.

[13] Wu, D., S. Tian, and W. Zhu, Modulating multidrug resistance to drug-based antitumor therapies through NF-kappaB signaling pathway: mechanisms and perspectives. *Expert Opin Ther Targets*, 2023. 27(6): p. 503-515.

[14] Hsu, H.H., et al., Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. *J Cell Physiol*, 2018. 233(7): p. 5458-5467.

[15] Wang, Z., et al., Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-kappaB-Nrf2 signaling in colorectal cancer cell. *Phytomedicine*, 2021. 82: p. 153414.

[16] Zhang, D. and D. Fan, Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. *Expert Rev Anticancer Ther*, 2007. 7(10): p. 1369-78.

[17] Zeng, X., et al., The Roles of microRNAs in Multidrug-Resistance Mechanisms in Gastric Cancer. *Curr Mol Med*, 2020. 20(9): p. 667-674.

[18] Duan, C., et al., Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. *Biomed Pharmacother*, 2023. 162: p. 114643.

[19] Zhang, D. and D. Fan, New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. *Future Oncol*, 2010. 6(4): p. 527-37.

- [20] Mowla, M. and A. Hashemi, Functional roles of exosomal miRNAs in multi-drug resistance in cancer chemotherapeutics. *Exp Mol Pathol*, 2021. 118: p. 104592.
21. Yang Jian and Zhou Yejiang, study on multidrug resistance protein levels in AFP positive gastric cancer. *Journal of Gastroenterology and Hepatology*, 2017.26 (12): p. 1365-1369.
- [22] Tan, W., et al., Deciphering the metabolic role of AMPK in cancer multi-drug resistance. *Semin Cancer Biol*, 2019. 56: p. 56-71.
- [23] Kaur, G., et al., Drug-metabolizing enzymes: role in drug resistance in cancer. *Clin Transl Oncol*, 2020. 22(10): p. 1667-1680.
- [24] Estrada, D.F., et al., Crystal Structures of Drug-Metabolizing CYPs. *Methods Mol Biol*, 2021. 2342: p. 171-192.
- [25] de Man, F.M., et al., Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. *Clin Pharmacokinet*, 2018. 57(10): p. 1229-1254.
- [26] Knights, K.M., A. Rowland, and J.O. Miners, Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). *Br J Clin Pharmacol*, 2013. 76(4): p. 587-602.
- [27] Zhang Li, et al., Bcl-2, and the significance of its expression in paclitaxel-resistant gastric adenocarcinoma cells. *Journal of Anhui Medical University*, 2014.49 (8): p. 1048-1052.
- [28] Geng, M., et al., The association between chemosensitivity and Pgp, GST-pi and Topo II expression in gastric cancer. *Diagn Pathol*, 2013. 8: p. 198.
- [29] Alam, M. and R. Mishra, Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer. *Life Sci*, 2021. 280: p. 119705.
- [30] Sciskalska, M. and H. Milnerowicz, The role of GSTpi isoform in the cells signalling and anticancer therapy. *Eur Rev Med Pharmacol Sci*, 2020. 24(16): p. 8537-8550.
- [31] Bui, A.T.N., et al., Artificial intelligence-based identification of octenidine as a Bcl-xL inhibitor. *Biochem Biophys Res Commun*, 2022. 588: p. 97-103.
- [32] Shishido, Y., et al., A Covalent Inhibitor for Glutathione S-Transferase Pi (GSTP(1-1)) in Human Cells. *Chembiochem*, 2019. 20(7): p. 900-905.
- [33] Mollazadeh, S., et al., Structural and functional aspects of P-glycoprotein and its inhibitors. *Life Sci*, 2018. 214: p. 118-123.